Selvita presents new data from SEL120 program during Leukemia and Lymphoma – Europe and the USA Linking Knowledge and Practice

Krakow, Poland – 03 October – Selvita (WSE:SLV), a clinical stage drug discovery and development company focused on innovative medicines for oncology patients and drug discovery services, will participate and present during the “Leukemia and Lymphoma – Europe and the USA Linking Knowledge and Practice”, which is taking place 3 – 5 October in Dubrovnik, Croatia. The conference is a joint effort of The University of Texas MD Anderson Cancer Center, Houston, Texas, USA and The School of Medicine, University of Zagreb, Zagreb, Croatia.

Selvita representatives will present new data in SEL120 program from Selvita’s R&D Pipeline during Oral Poster Presentation Session on Thursday, October 4th at 18:15. The talk and poster presentation is titled: “CDK8 inhibitor SEL120 targets AML by regulation of transcriptional programs involved in the maintenance of leukemia stem cells”. The session will take place in Elafiti Hall at Hotel Valamar in Dubrovnik, Croatia.

The Leukemia and Lymphoma Conference is dedicated to establishing links between European and US clinical scientists and physicians and advancing research in the field on hematooncology. Leukemia and Lymphoma 2018 will host nearly 500 delegates and approximately 50 renowned faculty from the USA and Europe. The meeting program will include presentations, round-table discussions, debates with audience participation and oral abstracts poster sessions.

 

To find more about the conference:
https://www.globalacademycme.com/content/leukemia-and-lymphoma-europe-and-usa-dubrovnik

 

 


Selvita Oncology Pipeline
In its internal research and development efforts, Selvita focuses on different dimensions of oncology. The company’s most advanced R&D program is SEL24, a dual PIM/FLT3 kinase inhibitor currently in Phase I/II clinical study, licensed to Menarini Group. The second most advanced program is SEL120, the first-in-class small molecule inhibitor of CDK8 with potential use in hematological malignancies, colorectal cancer and breast cancer, currently in IND-enabling studies. In August 2017 Selvita signed a partnering agreement with The Leukemia and Lymphoma Society for preclinical and Phase I clinical development of SEL120 in area of AML, within the Therapy Acceleration Program. Selvita Early Discovery Programs are focused on a number of novel oncology targets in the area of kinase inhibitors, cancer metabolism & immunometabolism and immunooncology.

 

About Selvita
Selvita S.A. is a clinical stage drug discovery company engaged in the research and development of novel cancer therapies, as well as provision of integrated drug discovery services. Selvita is headquartered in Krakow, Poland, with offices in the USA (Greater Boston, San Francisco Bay), and in the UK (Cambridge). Selvita has currently several projects at early or late discovery stage. Drug discovery clients of Selvita include numerous large and medium-sized pharmaceutical and biotechnology companies from USA and Europe. The company is listed on the Warsaw Stock Exchange (WSE:SLV).

 

Media contact:
Malgorzata Syjud
Selvita S.A.
malgorzata.syjud@selvita.com
+48 660 797 362

Click to share!: